Mohammad Esmaeeli; Anoush Azarfar; Aghilollah Keykhosravi; Mahbobeh Nematshahi; Yalda Ravanshad; Ahmad Delbari; Effat SheykhBaheddin zadeh
Volume 20, Issue 5 , March and April 2014, , Pages 597-602
Abstract
Aims: Acute kidney injury (AKI) is characterized by a reversible increase in the blood concentration of creatinine and nitrogenous waste products and by the inability of the kidney to regulate fluid and electrolyte homeostasis appropriately.
Hyperuricemia is a feature of several pathologies and requires ...
Read More
Aims: Acute kidney injury (AKI) is characterized by a reversible increase in the blood concentration of creatinine and nitrogenous waste products and by the inability of the kidney to regulate fluid and electrolyte homeostasis appropriately.
Hyperuricemia is a feature of several pathologies and requires an appropriate and often early treatment, owing to the severe consequences that it may cause. A rapid and massive raise of uric acid, mainly damage the kidney.. Rasburicase, compared to allopurinol, results in more rapid reduction of uric acid and prevent its accumulation in patients with hematologic malignancy with hyperuricemia and AKI.
Methods: We evaluated the efficacy of rasburicase (0.15 mg/kg) administered as single dose in 15 patient with AKI in sheikh hospital, Mashhad University of medical Sciences. Beside conventional therapy, infusion of Rasburicase in 50cc normal saline in30 minute intravenously was done and all adverse reaction was treated.
Before injection of Rasburicase and 1st, 3nd and 7rd day after it urea, creatinine, uric acid and urine output were determined and compared.
Results: Within first 24 hour, the levels of serum uric acid in all patients decreased dramatically. there was a significant improvement in estimated GFR and urine output. Urea and creatinine level decreased from Day 0 to Day 7 but there was no difference between creatinine before treatment and 1st day.
Conclusion: Rasburicase is effective for management of hyperuricemia and uremia in AKI Patients